NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Anti-HIV-1 p24 Hybridoma (183-H12-5C)
Catalog Number:	1513
Lot Number:	080164
Release Category:	C
Provided:	1 vial frozen cells, 1.42 x 10^6 cells/mL. Viability 92%.
Cell Type:	Balb/c mouse splenocyte x SP2-0 myeloma.
Isotype:	$IgG_{1, k}$
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%.
Freeze Medium:	RMPI 1640, 40%; fetal bovine serum, 50%; DMSO, 10%.
Growth Characteristics:	Addition of mouse spleen feeder cells (see attached instructions) is suggested for establishing these cells in culture.
Special Characteristics:	These cells produce an IgG_1 monoclonal antibody reactive with HIV-1 p24 Gag. The antibody has been used to study ethanol fixed cells in indirect fluorescence and immunoperoxidase assays, to immunoprecipitate p24, and to coat plates for p24 antigen capture ELISA. **Related Protocol:** Thawing and Propagation of Hybridomas Column Purification of Hybridoma 183 (HIV-1 p24) Supernatant
Sterility:	Negative for mycoplasma, bacteria and fungi.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage:	Liquid nitrogen
Contributor:	Dr. Bruce Chesebro and Dr. Hardy Chen.
References:	Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. *J Virol* **66**:6547-6554, 1992.
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 p24 Hybridoma (183-H12-5C) from Dr. Bruce Chesebro." Also include the reference cited above in any publications. **Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer, Email: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.**
Last Updated	September 01, 2016

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.